Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 11,581 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $38.92, for a total transaction of $450,732.52. Following the completion of the transaction, the chief financial officer now owns 112,933 shares of the company’s stock, valued at $4,395,352.36. This trade represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.27 during mid-day trading on Wednesday, reaching $42.12. 17,282,216 shares of the company traded hands, compared to its average volume of 11,375,842. The stock has a market cap of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35. The company’s fifty day moving average is $29.58 and its two-hundred day moving average is $22.86. Hims & Hers Health, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $44.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same period last year, the business posted ($0.04) EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, Piper Sandler increased their target price on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently made changes to their positions in HIMS. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth approximately $28,000. Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. US Bancorp DE lifted its stake in shares of Hims & Hers Health by 346.7% in the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after buying an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth about $48,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.